Aldeyra Therapeutics (ALDX) Enterprise Value (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Enterprise Value came in at -$40.9 million in Q1 2026, up 54.64% YoY from -$26.4 million in Q1 2025, and up 41.67% on a QoQ basis from -$70.0 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Enterprise Value (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Enterprise Value data on file, last reported at -$40.9 million in Q1 2026.
- Quarterly Enterprise Value rose 54.64% year-over-year to -$40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.9 million (up 54.64% YoY) and the FY2025 annual result came in at -$70.0 million, up 30.76% from the prior year.
- Enterprise Value climbed to -$40.9 million in Q1 2026, from -$70.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$14.3 million in Q4 2023 to a low of -$174.3 million in Q4 2022.
- A 5-year average of -$108.0 million and a median of -$101.2 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 91.79% — and 2024, when it tumbled 606.73%.
- Tracing ALDX's Enterprise Value over 5 years: stood at -$174.3 million in 2022, then jumped by 91.79% to -$14.3 million in 2023, then plunged by 606.73% to -$101.2 million in 2024, then jumped by 30.76% to -$70.0 million in 2025, then jumped by 41.67% to -$40.9 million in 2026.
- The last three Enterprise Value figures came in at -$40.9 million (Q1 2026), -$70.0 million (Q4 2025), and -$70.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | -45.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.09 Mn |
| Mar 31, 2026 | -40.85 Mn |
| Dec 31, 2025 | -70.04 Mn |
| Sep 30, 2025 | -70.94 Mn |
| Jun 30, 2025 | -81.92 Mn |
| Mar 31, 2025 | -90.06 Mn |
| Dec 31, 2024 | -101.15 Mn |
| Sep 30, 2024 | -72.74 Mn |
| Jun 30, 2024 | -80.33 Mn |
| Mar 31, 2024 | -146.02 Mn |
| Dec 31, 2023 | -14.31 Mn |
| Sep 30, 2023 | -143.33 Mn |
| Jun 30, 2023 | -151.68 Mn |
| Mar 31, 2023 | -165.03 Mn |
| Dec 31, 2022 | -174.30 Mn |
| Sep 30, 2022 | -163.83 Mn |
| Jun 30, 2022 | -117.69 Mn |
| Mar 31, 2022 | -151.87 Mn |
| Dec 31, 2021 | -129.43 Mn |
| Sep 30, 2021 | -116.37 Mn |